GoodRx Holdings, Inc.
GDRX
Positions held
Your positionsGDRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- GoodRx operates in a growing healthcare technology sector, providing valuable services that enhance consumer access to medications.
- Revenue increased by 3% compared to the previous quarter, reaching $200 million.
- Operating margin expanded to 11.8%, indicating improved operational efficiency.
- The company has experienced a revenue decline of 1.3% year-over-year, signaling potential challenges in market demand.
- Net income dropped significantly by 44.5% compared to the previous year, reflecting profitability issues.
- Trailing PE ratio stands at 65.4, suggesting that the stock may be overvalued relative to its earnings.
Fundamentals
| Market cap | $1.15B | Enterprise value | $1.39B | Trailing P/E | 67.20 | Forward P/E | 9.47 |
| PEG | — | Price / book | 1.76 | Beta | 1.69 | Dividend yield | 0.00% |
| Revenue growth | -1.3% | Earnings growth | -44.5% | Gross margin | 90.8% | Operating margin | 11.8% |
| Profit margin | 2.1% | ROE | 2.5% | ROA | 3.0% | Debt / equity | 0.83 |
| Current ratio | 1.38 | Free cash flow | $112.50M | Analyst recommendation | hold | Mean target | $3.95 |
| 52w high | $4.72 | 52w low | $1.77 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $200M | $194M | $195M | $196M | $203M |
| Op margin | 11.8% | 7.2% | 11.6% | 7.5% | 13.2% |
| Net income | $8.5M | $1.2M | $5.4M | $1.1M | $12.8M |
| Gross margin | 89.5% | 89.6% | 91.0% | 93.2% | 93.4% |
| Gross profit | $179M | $174M | $177M | $183M | $190M |
| Operating income | $23.6M | $14.0M | $22.7M | $14.6M | $26.8M |
- Revenue +3% vs prior quarter ($200M vs $194M).
- Gross margin 89.5% (was 89.6% prior quarter).
- Operating margin expanded to 11.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $797M | $792M | $750M | $767M | — |
| Op margin | 11.0% | 8.3% | -3.6% | 0.2% | — |
| Net income | $30.4M | $16.4M | -$8.9M | -$32.8M | — |
| Gross margin | 92.8% | 93.9% | 91.1% | 91.5% | — |
| Gross profit | $739M | $744M | $683M | $701M | — |
| Operating income | $87.5M | $65.8M | -$27.0M | $1.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · 3 Cash-Producing Stocks We Steer Clear Of
2026-10-05 · 3 Reasons to Avoid GDRX and 1 Stock to Buy Instead
2026-10-01 · Amazon (AMZN) and GoodRx (GDRX) Chase Prescription Subscribers as Insurance Coverage Slips
2026-09-29 · 1 Value Stock to Target This Week and 2 That Underwhelm
2026-09-14 · 3 of Wall Street’s Favorite Stocks We Approach with Caution
2026-09-03 · From Kids to Canines: GoodRx Launches Companion Family Plan to Bring Healthcare Savings to the Whole Household
2026-09-01 · 1 Momentum Stock with Exciting Potential and 2 That Underwhelm
2026-08-14 · Reflecting On Healthcare Technology Stocks’ Q2 Earnings: GoodRx (NASDAQ:GDRX)
2026-08-13 · 1 Small-Cap Stock with Solid Fundamentals and 2 Facing Headwinds
2026-08-13 · GoodRx (GDRX) Stock Looks Overvalued On Its Earnings Outlook
2026-08-13 · GoodRx Holdings (GDRX) Could Be 13% Overvalued After Q2 Earnings and Guidance Raise
2026-08-12 · GoodRx (GDRX) Q2 2026 Earnings Call Transcript
Price (daily)
Full chart · RSI · MACD · patterns